Related Experiment Video
Updated: Aug 2, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Minimal residual disease in multiple myeloma
Nour Moukalled1, Florent Malard2, Ali Bazarbachi1
1Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Abstract:
Minimal Residual Disease (MRD) in multiple myeloma has emerged as a significant prognostic factor, guiding treatment strategies and enhancing patient outcomes. Despite advancements in therapies such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapy, and bispecific antibodies, complete eradication of malignant plasma cells remains challenging. MRD refers to a small number of residual cancer cells that persist after treatment and require sensitive methods like next-generation flow cytometry (NGF) and next-generation sequencing (NGS) for detection. MRD negativity has been associated with improved progression-free survival (PFS) and overall survival (OS), making it a key marker in clinical trials. The clinical utility of MRD lies in its ability to predict outcomes, with sustained MRD negativity linked to prolonged survival. Furthermore, it will likely help in tailoring treatment approaches, such as therapy escalation for high-risk patients or de-escalation for those achieving MRD negativity. Despite its prognostic value, challenges remain in standardizing MRD testing, ensuring its widespread availability, and addressing variability in results based on different detection methods. Future research aims to refine MRD-guided treatment and explore novel detection techniques, such as liquid biopsies, to improve patient monitoring in multiple myeloma.
Insights
Minimal Residual Disease (MRD) detection is crucial in multiple myeloma. Achieving MRD negativity correlates with better survival, guiding future treatment strategies for patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Minimal Residual Disease (MRD) is a key prognostic factor in multiple myeloma, influencing treatment decisions and patient outcomes.
- Despite advanced therapies, complete eradication of malignant plasma cells remains difficult.
- Sensitive detection methods are essential for identifying residual disease.
Purpose of the Study:
- To highlight the prognostic significance of MRD in multiple myeloma.
- To discuss the role of MRD negativity in predicting patient survival and guiding treatment adjustments.
- To address the challenges and future directions in MRD monitoring.
Main Methods:
- Utilizing sensitive techniques such as next-generation flow cytometry (NGF) and next-generation sequencing (NGS) for MRD detection.
- Analyzing the association between MRD status and clinical outcomes like progression-free survival (PFS) and overall survival (OS).
- Reviewing current and emerging therapeutic strategies in multiple myeloma.
Main Results:
- MRD negativity is strongly associated with improved PFS and OS in multiple myeloma patients.
- Sustained MRD negativity predicts prolonged survival and supports treatment de-escalation.
- MRD status can guide therapy escalation for high-risk individuals.
Conclusions:
- MRD is a vital biomarker for predicting outcomes and personalizing treatment in multiple myeloma.
- Standardization of MRD testing and accessibility remain critical challenges.
- Future research should focus on refining MRD-guided therapies and exploring novel detection methods like liquid biopsies.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
07:53Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...